American Society of Hirudotherapy

Modulation of clearance of recombinant serum albumin by either glycosylation or truncation

Research article published in Thrombosis research (2000)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: In vitro / laboratoryGenomics & ProteomicsDrug DevelopmentSalivary PharmacologySheffield WP et al. · Thrombosis research, 2000

Abstract

Albumin is an abundant non-glycosylated plasma protein with a slow clearance profile. It has been employed as a fusion partner in efforts to slow the clearance of small antithrombotic proteins like hirudin. In the present study, the in vivo clearance of recombinant rabbit serum albumin (rRSA), of mutant rRSAs containing consensus sequences for N-linked glycosylation (D494N and V14T variants), and of mutant mini-proteins truncated at albumin domain boundaries (rRSAs 1-185, 1-377, or 378-584) was examined. Mean terminal catabolic half-lives (t(0.5)cat) in rabbits for plasma-derived RSA, rRSA, and the V14T variant did not differ significantly (range 4. 32-4.76 days). In contrast, mean t(0.5)cat was reduced to 2.87 days for the D494N variant and to less than 0.071 days for all mini-proteins. The mini-proteins were found in the urine in tissue distribution experiments, suggesting a renal route of clearance. Our results suggest that all three internally repeated albumin domains are required to maintain the slow in vivo clearance profile of albumin, and that albumin glycosylation can be associated with an acceleration of clearance. This information could be used to design fusion proteins, including those with antithrombotic properties, with predictably altered in vivo half-lives less than that of serum albumin.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, Non-U.S. Gov't
Indexed MeSH termsAnimalsAutoradiographyElectrophoresis, Polyacrylamide GelGlycosylationHalf-LifeInjectionsIodine RadioisotopesMaleMutagenesis, Site-DirectedProtein EngineeringRabbitsRecombinant ProteinsSerum AlbuminTime FactorsTissue Distribution

Summary

In rabbits, N-linked glycosylation at residue 494 shortened recombinant albumin catabolic half-life to 2.87 days, whereas domain-truncated mini-albumins appeared in urine and cleared within hours, findings relevant to designing hirudin fusion proteins of predictable half-life.

Context

This study examined how glycosylation and domain truncation affect the in vivo clearance of recombinant rabbit serum albumin (rRSA) in rabbits, finding that all three internally repeated albumin domains are required to maintain albumin's slow clearance profile and that introduced glycosylation (D494N variant) accelerated clearance, reducing half-life from ~4.3 to 2.87 days. The authors note that albumin has been used as a fusion partner to slow clearance of small antithrombotic proteins like hirudin, and that their findings could inform the design of such fusion proteins with predictably altered half-lives. The study provides pharmacokinetic design principles applicable to hirudin-based therapeutics, but does not directly involve hirudin, leeches, or any leech-derived molecule.

Citation

Reference (Vancouver style)

Sheffield WP, Marques JA, Bhakta V, Smith IJ. Modulation of clearance of recombinant serum albumin by either glycosylation or truncation. Thromb Res. 2000;99(6):613-621. doi:10.1016/s0049-3848(00)00286-3. PMID: 10974348

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 27, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.